Quantcast

Latest Paliperidone Stories

2014-09-24 16:26:18

JANSSEN® CONNECT® program seeks to provide people living with schizophrenia information and assistance to support healthcare provider-ordered long-acting antipsychotic treatment TITUSVILLE, N.J., Sept. 24, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. announced the results of a first-of-its-kind study, The Impact of JANSSEN(®) CONNECT(®) Injection Centers on Adherence to an Atypical Long-Acting Injectable Antipsychotic among Patients with Schizophrenia Enrolled in a Support Program....

2014-07-14 08:26:29

Submission based on first head-to-head study vs. oral treatments in real world context TITUSVILLE, N.J., July 14, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking a label change that, if approved, would include new data showing significantly delayed time to relapse in patients prescribed once-monthly atypical long-acting antipsychotic INVEGA(®)...

2014-05-13 08:33:18

New submission based on positive data from a 15-month schizoaffective relapse prevention study TITUSVILLE, N.J., May 13, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the submission of supplemental New Drug Applications (sNDAs) for once-monthly atypical long-acting antipsychotic INVEGA(®) SUSTENNA(®) (paliperidone palmitate) to the U.S. Food and Drug Administration (FDA) for approval to treat schizoaffective disorder as either monotherapy or adjunctive...

2014-05-07 23:14:54

Flood Law Group announced today that it is now available to investigate claims related to complications from taking prescription Invega extended release tablets. Invega, also known by its generic name paliperidone, may contribute to an increased risk of leukopenia and neutropenia and gynecomastica according to the FDA. Washington, D.C. (PRWEB) May 07, 2014 Flood Law Group released a statement today announcing that it is now available to investigate potential claims on behalf of people who...

2014-05-06 16:32:22

Demonstrated significant efficacy in manic and depressive mood symptoms and psychosis, and improved patient functioning TITUSVILLE, N.J., May 6, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the results of the company's schizoaffective relapse prevention study of once-monthly atypical long-acting antipsychotic INVEGA(®) SUSTENNA(® )(paliperidone palmitate). The trial found INVEGA(®) SUSTENNA(®) met its primary endpoint of delayed time to and reduced risk of...

2014-05-05 08:29:33

First prospective, randomized clinical trial to reflect context of "real world" issues in treating schizophrenia, including recent incarceration and substance abuse TITUSVILLE, N.J., May 5, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the results of its landmark PRIDE (Paliperidone Palmitate Research In Demonstrating Effectiveness) trial. PRIDE is the first prospective, randomized clinical trial to compare schizophrenia medications within the context of many...

2014-04-22 08:34:04

TITUSVILLE, N.J., April 22, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., and Janssen Research and Development, LLC, both members of the Johnson & Johnson Family of Companies, announced that several posters related to the company's work in mental health will be featured at the 167(th) Annual Meeting of the American Psychiatric Association (APA) in New York City May 3 to 7. The posters are: -- Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE):...

2014-04-06 23:01:17

Study Released as Risperdal Lawsuits Alleging Use of Antipsychotic Drug Caused Gynecomastia (Male Breast Growth) in Men and Boys Continue to Move Forward in Pennsylvania Columbus, OH (PRWEB) April 06, 2014 Wright & Schulte LLC, an experienced law firm representing clients in Risperdal lawsuits, notes that a new study has linked use of the atypical antipsychotic medication to gynecomastia, or male breast growth. The release of the study, which was presented in March at the 2014 Annual...

2014-04-02 23:01:07

The Firm continues to investigate Risperdal lawsuits that allege the atypical antipsychotic drug caused male breast development, or gynecomastia. New York, New York (PRWEB) April 02, 2014 The nationwide law firm of Bernstein Liebhard LLP is actively filing Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) on behalf of individuals who allegedly suffered gynecomastia, or male breast growth, due to their use of the atypical antipsychotic. On March 26, 2014, the Firm filed a claim...

2014-03-20 08:29:49

Independent Data Monitoring Committee Recommends Halting Trial and Unblinding Data Based on Treatment Efficacy TITUSVILLE, N.J., March 20, 2014 /PRNewswire/ -- Janssen Research & Development, LLC announced today that following an Independent Data Monitoring Committee (IDMC) recommendation based on positive efficacy, it has halted early a Phase 3 clinical study of paliperidone palmitate 3-month formulation, an investigational treatment for symptoms of schizophrenia in adults. "We are...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related